Platinum-resistant Ovarian Cancer - A Pipeline Analysis Report

Overview of the drug development pipeline for platinum-resistant ovarian cancer

Ovarian cancer is the most lethal gynecologic malignancy. It is formed in or on an ovary. This cancer can spread to the abdominal lining, lungs, and liver. It is difficult to detect ovarian cancer in the early stages, giving the asymptomatic nature of this indication. It reduces patients’ survival span, which is usually less than five years since the genesis of the tumor. Ovarian cancer can be classified in two types on the reaction to chemotherapy drugs. The types are platinum-sensitive and platinum-resistant ovarian cancer. As per the NIH, patients with ovarian cancer have less than 47% chances of surviving for more than five years. The prevalence of this disease in unevenly distributed while being more common in less developed countries compared to the advanced economies. About 58% of ovarian cancer cases are from less developed countries. The disease is also very common in older women. In 2015, 28% of all the new cases of ovarian cancer were in women aging above 75 years. Consequently, Technavio’s market research analysts suggest with the increase in instances of ovarian cancer, the drug development for platinum-resistant ovarian cancer has been promoted.

According to this pipeline analysis report, most of the drug development molecules in the pipeline are being developed for the treatment of platinum-resistant recurrent ovarian cancer. Our market research analysts have also identified that most of these molecules are in the pre-clinical development stage and a considerable number of molecules have been discontinued from development.

Companies covered

This pipeline analysis report provides a detailed analysis of the companies that are involved in the development for the drug development molecules for the treatment of ovarian cancer. In addition to providing information on the various stages of molecules developed by companies for different indications, this pipeline analysis report also provides information about the drug development molecules discontinued by companies.

Some of the companies covered in this pipeline analysis report are –

• Bayer
• Novartis
• Celgene
• Eli Lilly
• Pfizer

Therapeutic assessment of the drug development pipeline for platinum-resistant ovarian cancer by route of administration

• Intravenous
• Oral
• Subcutaneos
• Intradermal
• Intraperitoneal

The intravenous route of administration (ROA) involves the application of the drug directly into the veins, which will have a more direct effect on the target cells.

Therapeutic assessment of the drug development pipeline for platinum-resistant ovarian cancer by therapy

• Monotherapy
• Combination therapy

According to this pipeline analysis report, all the molecules that are currently in the drug development pipeline for platinum-resistant ovarian cancer are being developed as combination therapy drugs and most of these molecules are in the pre-clinical stage of development.

Key questions answered in the report include

• What are the drug development molecules in the various development stages for platinum-resistant ovarian cancer?
• What are the companies that are currently involved in the development of drug development molecules for platinum-resistance ovarian cancer?
• Insight into discontinued/inactive molecules with appropriate reasoning?
• What are the major regulatory authorities approving drugs in various regions?
• Detailed profiling of each active molecule

Technavio also offers customization on reports based on specific client requirement.